Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it’s making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics (NASDAQ: VKTX) are up a modest 3.3%.

This article was originally published here.